Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768

KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene

Cartron, G., Dacheux, L., Salles, G. A., Solal‐Céligny, P., BARDOS, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,954

Cetuximab for the Treatment of Colorectal Cancer

Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904

Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694

KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

Lièvre, A., Bachet, J., Boige, V., Cayre, A., Corre, D. L., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,485

Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma

Weng, W., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,324

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125

Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity

Xu, Y., Xiao, Y. Z., Luo, C., Liu, Q., Wei, A., Yang, Y., Zhao, L., & Wang, Y. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106584 · Cited by 20

NK Cell-based Immunotherapies in Pediatric Oncology

McDowell, K. A., Hank, J. A., DeSantes, K. B., Capitini, C. M., Otto, M., & Sondel, P. M. (2015) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000303 · Cited by 19

Antitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-Engineering

Xu, H., Guo, H.-F., Cheung, I. Y., & Cheung, N. V. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0221 · Cited by 19

FcγRIIA and IIIA polymorphisms predict clinical outcome of trastuzumab-treated metastatic gastric cancer

Wang, D., Wei, X., Wang, Z.-Q., Lu, Y., Shi, S.-M., Wang, N., Qiu, M., Wang, F.-H., Wang, R.-J., Li, Y., et al. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s142620 · Cited by 19

Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment

Hirvinen, M., Heiskanen, R., Oksanen, M., Pesonen, S. K., Liikanen, I., Joensuu, T. K., Kanerva, A., Cerullo, V., & Hemminki, A. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-193 · Cited by 19

Tumor Antigen-Specific Monoclonal Antibodies and Induction of T-Cell Immunity

Trivedi, S., Jie, H.-B., & Ferris, R. L. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.08.003 · Cited by 18

Expression of human FcγRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding

Armour, K. L., Smith, C. S., & Clark, M. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.01.011 · Cited by 18

Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies

Ajina, R., Zahavi, D. J., Zhang, Y., & Weiner, L. M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.005 · Cited by 18

Current situation of zalutumumab

Rivera, F., Salcedo, M., Vega, N., Blanco, Y., & López, C. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902932871 · Cited by 18

Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex

van Rees, D. J., Bouti, P., Klein, B. J. A. M., Verkuijlen, P., van Houdt, M., Schornagel, K., Tool, A. T. J., Venet, D., Sotiriou, C. P., El-Abed, S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004820 · Cited by 19

Fcγ Receptor Polymorphisms and Clinical Efficacy of Rituximab in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Zhuang, Y., Xu, W., Shen, Y., & Li, J. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.067 · Cited by 17

The head and neck cancer genome in the era of immunotherapy

Wijetunga, N. A., Yu, Y., Morris, L. G. T., Lee, N. Y., & Riaz, N. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105040 · Cited by 17

Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus

Hargreaves, C. E., Iriyama, C., Rose-Zerilli, M. J. J., Nagelkerke, S. Q., Hussain, K., GANDERTON, R. H., Lee, C., Machado, L. R., Hollox, E. J., Parker, H., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142379 · Cited by 17

Functional Interactions of Common Allotypes of Rhesus Macaque FcγR2A and FcγR3A with Human and Macaque IgG Subclasses

Grunst, M. W., Grandea, A. G., Janaka, S. K., Hammad, I., Grimes, P., Karl, J. A., Wiseman, R. W., O’Connor, D. H., & Evans, D. T. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000501 · Cited by 16

Inhibiting N‐glycan processing increases the antibody binding affinity and effector function of human natural killer cells

Rodríguez, M. C., Hughes, H. B., Kremer, P. G., Subedi, G. P., & Barb, A. W. (2023) · Immunology · doi:10.1111/imm.13662 · Cited by 18

FCGR2C genotyping by pyrosequencing reveals linkage disequilibrium with FCGR3A V158F and FCGR2A H131R polymorphisms in a Caucasian population

Lejeune, J., Piégu, B., Gouilleux‐Gruart, V., Ohresser, M. C. P., Watier, H., & Thibault, G. (2012) · mAbs · doi:10.4161/mabs.22287 · Cited by 16

Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy

Makkouk, A., H, V. S. M. P., Chester, C., Chang, S., Colevas, A. D., Sunwoo, J. B., Maecker, H. T., Desai, M., & Kohrt, H. E. K. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw570 · Cited by 16

Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas

Fiedler, W., Cresta, S., Schulze‐Bergkamen, H., Dosso, S. D., Weidmann, J., Tessari, A., Baumeister, H., Danielczyk, A., Dietrich, B., Goletz, S., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000303 · Cited by 16

Cetuximab Promotes Immunotoxicity Against Rhabdomyosarcoma In Vitro

Herrmann, D., Seitz, G., Warmann, S. W., von Bonin, M., Fuchs, J., & Armeanu–Ebinger, S. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181c549b0 · Cited by 16

scFv-Based “Grababody” as a General Strategy to Improve Recruitment of Immune Effector Cells to Antibody-Targeted Tumors

Cai, Z., Fu, T., Nagai, Y., Lam, L., Yee, M., Zhu, Z., & Zhang, H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3920 · Cited by 15

Challenges in the harmonization of immune monitoring studies and trial design for cell-based therapies in the context of hematopoietic cell transplantation for pediatric cancer patients

Nierkens, S., Lankester, A. C., Egeler, R. M., Bader, P., Locatelli, F., Pulsipher, M. A., Bollard, C. M., & Boelens, J. J. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.09.008 · Cited by 15

Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?

Deligne, C., Milcent, B., Josseaume, N., Teillaud, J., & Sibéril, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00950 · Cited by 15

Characterization of human natural killer cells for therapeutic use.

Wagner, A., Alici, E., & Lowdell, M. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2018.11.001 · Cited by 12

FcγR and EGFR Polymorphisms as Predictive Markers of Cetuximab Efficacy in Metastatic Colorectal Cancer

Inoue, Y., Hazama, S., Iwamoto, S., Miyake, Y., Matsuda, C., Tsunedomi, R., Okayama, N., Hinoda, Y., Yamasaki, T., Suehiro, Y., et al. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-014-0103-6 · Cited by 15

Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol

Ottaiano, A., Scala, S., Normanno, N., Napolitano, M., Capozzi, M., Rachiglio, A. M., Roma, C., Trotta, A. M., D’Alterio, C., Portella, L., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6109-z · Cited by 15

Antibody Engineering

Lo, K.-M., Léger, O. J. P., & Hock, B. M. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.aid-0007-12 · Cited by 14

Biomarker-Based Selection of Therapy For Colorectal Cancer

Ross, J. S. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.11.38 · Cited by 14

FCGR2A, FCGR3Apolymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer

Ying, H., Wang, F., Chen, X., He, B., Pan, Y., Jie, C., Liu, X., Cao, W.-J., Peng, H.-X., Lin, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4872 · Cited by 14

Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab

He, X., Cruz, J. L. G., Joseph, S. R., Pett, N., Chew, H. Y., Tuong, Z. K., Okano, S., Kelly, G., Veitch, M., Simpson, F., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24242 · Cited by 14

In situ vaccination at a peripheral tumor site augments response against melanoma brain metastases

Clark, P. A., Sriramaneni, R. N., Jin, W. J., Jagodinsky, J. C., Bates, A. M., Jaquish, A. A., Anderson, B. R., Le, T. Q. H., Lubin, J. A., Chakravarty, I., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000809 · Cited by 13

Isotype Selection and Fc Engineering: Design and Construction of Fit-for-Purpose Therapeutic Antibodies

Strohl, W. R. (2011) · Modecular medicine and medicinal · doi:10.1142/9781848166295_0005 · Cited by 13

A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer

du Roure, P. D., Lajoie, L., Mallavialle, A., Alcaraz, L. B., Mansouri, H., Fenou, L., Garambois, V., Rubio, L., David, T., Coënon, L., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007135 · Cited by 13

c-Abl Modulates Tumor Cell Sensitivity to Antibody-Dependent Cellular Cytotoxicity

Murray, J. C., Aldeghaither, D. S., Wang, S., Nasto, R. E., Jablonski, S. A., Tang, Y., & Weiner, L. M. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0083 · Cited by 13

Review Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer

Krawczyk, P. A., & Kowalski, D. M. (2014) · Współczesna Onkologia · doi:10.5114/wo.2013.38566 · Cited by 13

Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial

Brøndum, L., Alsner, J., Sørensen, B. S., Maare, C., Johansen, J., Primdahl, H., Evensen, J. F., Kristensen, C. A., Andersen, L. J., Overgaard, J., et al. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1464664 · Cited by 13

Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer

Misumi, T., Tanabe, K., Fujikuni, N., & Ohdan, H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204880 · Cited by 12

Role of trastuzumab in the management of HER2-positive metastatic breast cancer

Valabrega, G. (2010) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s6070 · Cited by 12

De la sérothérapie aux anticorps recombinants « nus »

Watier, H. (2009) · médecine/sciences · doi:10.1051/medsci/20092512999 · Cited by 13

A genetic variant of FcγRIIIa is strongly associatedwith humoral immunity to cyclin B1 in African American patients with prostate cancer

Pandey, J. P., Namboodiri, A. M., & Kistner‐Griffin, E. (2012) · Immunogenetics · doi:10.1007/s00251-012-0660-y · Cited by 12

SNPs rs4656317 and rs12071048 located within an enhancer in FCGR3A are in strong linkage disequilibrium with rs396991 and influence NK cell-mediated ADCC by transcriptional regulation

Oboshi, W., Watanabe, T., Yukimasa, N., Ueno, I., Aki, K., Tada, T., & Hosoi, E. (2016) · Human Immunology · doi:10.1016/j.humimm.2016.06.012 · Cited by 12

Hepatocellular carcinoma: Prospects for natural killer cell immunotherapy

Kumar, N., & Khakoo, S. I. (2018) · HLA · doi:10.1111/tan.13275 · Cited by 12

Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen

Kellner, C., Lutz, S., Oberg, H., Wesch, D., Otte, A., Diemer, K. J., Wilcken, H., Bauerschlag, D., Glüer, C., Wichmann, C. W., et al. (2021) · Biological Chemistry · doi:10.1515/hsz-2021-0229 · Cited by 15

Calicum microdomains form within neutrophils at the neutrophil–tumor cell synapse: role in antibody-dependent target cell apoptosis

Clark, A. J., Diamond, M. E., Elfline, M. A., & Petty, H. R. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0735-2 · Cited by 12

Pharmacogenomics and metastatic colorectal cancer: Current knowledge and perspectives

Benhaïm, L., LaBonte, M. J., & Lenz, H. (2011) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.640832 · Cited by 11

In vitro functional characterization of biosimilar therapeutic antibodies

Láng, J. A., Balogh, Z. C., Nyitrai, M. F., Juhász, C., Gilicze, A. K. B., Iliás, A., Zólyomi, Z., Bödör, C., & Rábai, E. (2020) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2020.11.010 · Cited by 11

Cancer Immunotherapy: Where Next?

Bodmer, W. F., & Golubovskaya, V. (2023) · Cancers · doi:10.3390/cancers15082358 · Cited by 11

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

Borrero‐Palacios, A., Cebrián, A., del Pulgar, M. T. G., García‐Carbonero, R., Alfonso, P. G., Aranda, E., Élez, E., López‐López, R., Cervantes, A. M. R., Valladares, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39291-2 · Cited by 11

Impact of molecular markers on treatment selection in advanced colorectal cancer

Prenen, H., Tejpar, S., & Cutsem, E. V. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70018-8 · Cited by 11

Single-nucleotide polymorphisms and copy number variations of the FCGR2A and FCGR3A genes in healthy Japanese subjects

Moriya, H., Saito, K., Helsby, N. A., Hayashi, N., Sugino, S., Yamakage, M., Sawaguchi, T., Takasaki, M., Takahashi, M., & Kurosawa, N. (2013) · Biomedical Reports · doi:10.3892/br.2013.210 · Cited by 10

KRAS status and resistance to epidermal growth factor receptor tyrosine‐kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta‐analysis

Li, W., Shi, Q., Wang, W., Liu, J., Ren, J., Li, Q., & Hou, F. (2014) · Colorectal Disease · doi:10.1111/codi.12749 · Cited by 10

FcγRIIaandFcγRIIIaPolymorphisms and Cetuximab Benefit in the Microscopic Disease

Sclafani, F., de Castro, D. G., Cunningham, D., Wilson, S. H., Peckitt, C., Capdevila, J., Glimelius, B. L. G., Roselló, S., Wotherspoon, A. C., Brown, G. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0674 · Cited by 10

An NK cell line (NK92-41BB) expressing high levels of granzyme is engineered to express the high affinity chimeric genes CD16/CAR

Zhao, H., Zhou, Z., Li, G., Liu, G., Lin, S., Chen, W., & Xiong, S. (2021) · Cytotechnology · doi:10.1007/s10616-021-00476-1 · Cited by 10

Gradual Increase of FcγRIIIa/CD16a Expression and Shift toward IFN-γ Secretion during Differentiation of CD56dim Natural Killer Cells

Lajoie, L., Congy‐Jolivet, N., Bolzec, A., & Thibault, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01556 · Cited by 10

The antibody-binding Fc gamma receptor IIIa / CD16a is N-glycosylated with high occupancy at all five sites

Lampros, E. A., Kremer, P. G., de león, J. S. A. D., Roberts, E. T., Rodríguez, M. C., Amster, I. J., & Barb, A. W. (2022) · Current Research in Immunology · doi:10.1016/j.crimmu.2022.05.005 · Cited by 9

Targeting CD16A on NK cells and GPC3 in hepatocellular carcinoma: development and functional validation of a therapeutic bispecific antibody

Chen, L., Zhu, Y., Feng, M., Zuo, D., Chen, G., & Ji, K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1599764 · Cited by 9

Rôle des récepteurs à la portion Fc des IgG (FcγRs) dans l’activité des anticorps thérapeutiques

Lejeune, J., Thibault, G., Cartron, G., Ohresser, M. C. P., & Watier, H. (2010) · Bulletin du Cancer · doi:10.1684/bdc.2010.1077 · Cited by 9

The colorectal cancer stem-like cell hypothesis: a pathologist's point of view.

Șușman, S., Tomuleasa, C., Soritau, O., Mihu, C., Rus-Ciuca, D., Sabourin, J., Bibeau, F., Irimie, A. I., & Buiga, R. (2012) · PubMed · Cited by 8

Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer

Rabia, E., Garambois, V., Dhommée, C., Larbouret, C., Lajoie, L., Buscail, Y., Jiménez-Domínguez, G., Choblet, S., Liaudet‐Coopman, E., Cérutti, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1168444 · Cited by 8

KRAS mutational analysis for colorectal cancerApplication: Pharmacogenomic

Wang, G., Kelley, R. K., & GAPPNet (2010) · PLoS Currents · doi:10.1371/currents.rrn1175 · Cited by 8

A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck – the RESGEX study

Klinghammer, K. F., Fayette, J., Kawecki, A., Dietz, A., Schafhausen, P., Folprecht, G., Rottey, S., Debourdeau, P., Lavernia, J., Jacobs, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100242 · Cited by 8

Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer

Loupakis, F., Cremolini, C., Fontanini, G., Stasi, I., Salvatore, L., & Falcone, A. (2009) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009348984 · Cited by 8

Evolving role of cetuximab in the treatment of colorectal cancer.

Schuch, G., Kobold, S., & Bokemeyer, C. (2009) · PubMed Central · Cited by 8

FcγR binding differentially contributes to protection by two human monoclonal antibodies targeting Plasmodium falciparum circumsporozoite protein

Kisalu, N. K., Pereira, L. D. S., Herman, J. D., Asokan, M., Ernste, K., Merriam, J. S., Liu, C., DeMouth, M. E., Pegu, A., Lofgren, M., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adk6745 · Cited by 7

Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients

Volz, N. B., Hanna, D. L., Stintzing, S., Zhang, W., Yang, D., Cao, S., Ning, Y., Matsusaka, S., Sunakawa, Y., Berger, M. D., et al. (2020) · Cancers · doi:10.3390/cancers12102947 · Cited by 7

Biotherapeutics and its applications in Microbiology

Kaur, N., & Chaudhary, V. (2021) · Environment Conservation Journal · doi:10.36953/ecj.2021.se.2207 · Cited by 7

KRAS mutation screening by chip-based DNA hybridization – a further step towards personalized oncology

Steinbach, C., Steinbrücker, C., Pollok, S., Walther, K., Clement, J. H., Chen, Y., Petersen, I., Cialla‐May, D., Weber, K., & Popp, J. (2015) · The Analyst · doi:10.1039/c4an02086c · Cited by 7

Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer

Jain, A. K., Poonia, B., So, E. C., Vyzasatya, R., Burch, E. E., Olsen, H. S., Mérigeon, E. Y., Block, D. S., Zhang, X., Schulze, D. H., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.009 · Cited by 7

Natural Killer (NK)- and T-Cell Engaging Antibody-Derived Therapeutics

Stein, C., Schubert, I. A., & Fey, G. H. (2012) · Antibodies · doi:10.3390/antib1010088 · Cited by 8

New and potential clinical applications ofKRASas a cancer biomarker

Kriegshäuser, G., Auner, V., & Zeillinger, R. (2010) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2010.510512 · Cited by 7

FCGR3Apolymorphism story: a new piece of the puzzle

Cartron, G. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190903161109 · Cited by 7

Fcγ Receptor Polymorphisms as Biomarkers for Epidermal Growth Factor Receptor Antibodies

Valerius, T. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.7342 · Cited by 7

Meta-analysis of the predictive value of KRAS mutations in treatment response using cetuximab in colorectal cancer.

Tsoukalas, N., Tzovaras, A. A., Tolia, M., Kostakis, I. D., Papakostidi, A., Pistamaltzian, N. F., & Ardavanis, A. (2012) · PubMed · Cited by 6

A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options

Eisner, F., Pichler, M., Goletz, S., Stoeger, H., & Samonigg, H. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-202996 · Cited by 6

Panitumumab and Cetuximab Affect Differently Mirna Expression in Colorectal Cancer Cells

Chautard, R., Corset, L., Ibrahim, S., Desvignes, C., Paintaud, G., Baroukh, N., Guéguinou, M., Lecomte, T., & Raoul, W. (2021) · Biomarkers in Medicine · doi:10.2217/bmm-2020-0520 · Cited by 6

Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC

Scarabel, L., Bignucolo, A., Toffoli, G., Cecchin, E., & Mattia, E. D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112468 · Cited by 6

Stratégies d’immunothérapie dans les cancers colorectaux

Tougeron, D., Fauquembergue, É., & Latouche, J. (2013) · Bulletin du Cancer · doi:10.1684/bdc.2013.1800 · Cited by 6

Sensitivity and resistance to EGF-R inhibitors

Peipp, M., Dechant, M., & Valerius, T. (2009) · mAbs · doi:10.4161/mabs.1.6.10051 · Cited by 6

Cetuximab-dependent ADCC in cancer: dream or reality?

Ottaiano, A., Scala, S., & Iaffaioli, V. R. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0884-3 · Cited by 6

Radiomics‐Based CT Prediction of KRAS/NRAS/BRAF Mutation Status in Colorectal Cancer: A Multicenter Study

Yang, Y., Zhang, C., Fu, D., Chen, J., Zhang, X., Pu, Z., Wang, G., & Li, Z. (2025) · Medicine Advances · doi:10.1002/med4.70012 · Cited by 5

Antibody dependent cell-mediated cytotoxicity selection pressure induces diverse mechanisms of resistance

Zahavi, D. J., Erbe, R., Zhang, Y., Guo, T. W., Malchiodi, Z. X., Maynard, R. E., Lekan, A. A., Gallagher, R. I., Wulfkuhle, J. D., Petricoin, E. F., et al. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2269637 · Cited by 6

Systematic Analysis of the Expression and Prognosis of Fcγ Receptors in Clear Cell Renal Cell Carcinoma

Nie, W., Yao, Y., Luo, B., Zhu, J., Li, S., Yang, X., Luo, T., Liu, W., & Shibing, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.755936 · Cited by 5

Macrophage-Based Therapeutic Strategies in Hematologic Malignancies

Khalili, S., Zeinali, F., Fard, A. M., Taha, S. R., Naghibi, A. F., Bagheri, K., Zadeh, M. S., Eslami, Y., Fattah, K., Asadimanesh, N., et al. (2023) · Cancers · doi:10.3390/cancers15143722 · Cited by 6

Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors

Muraro, E., Montico, B., Lum, B., Colizzi, F., Giurato, G., Salvati, A., Guerrieri, R., Rizzo, A., Comaro, E., Canzonieri, V., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1336566 · Cited by 5

Flow Cytometric Assessment of FcγRIIIa-V158F Polymorphisms and NK Cell Mediated ADCC Revealed Reduced NK Cell Functionality in Colorectal Cancer Patients

Schiele, P., Kolling, S., Rosnev, S., Junkuhn, C., Walter, A. L., von Einem, J. C., Stintzing, S., Schöning, W., Sauer, I. M., Modest, D. P., et al. (2024) · Cells · doi:10.3390/cells14010032 · Cited by 5

Integration of Anti-Epidermal Growth Factor Receptor Therapies With Cytotoxic Chemotherapy

Serrano, C., Markman, B., & Tabernero, J. M. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181e07670 · Cited by 5

Pharmacogenomics of Cetuximab in Metastatic Colorectal Carcinoma

Silvestris, N., Vincenzi, B., Brunetti, A. E., Loupakis, F., Dell’Aquila, E., Russo, A. D., Scartozzi, M., Giampieri, R., Cascinu, S., Lorusso, V., et al. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.124 · Cited by 5

Scientific Significance of Clinically Insignificant FcγRIIIa-V158F Polymorphism

Cartron, G., Houot, R., & Kohrt, H. E. K. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2777 · Cited by 5

Function-structure approach reveals novel insights on the interplay of Immunoglobulin G 1 proteoforms and Fc gamma receptor IIa allotypes

Lippold, S., Mistry, K., Lenka, S., Whang, K., Liu, P., Pitschi, S., Kuhne, F., Reusch, D., Cadang, L., Knaupp, A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1260446 · Cited by 5

Application of Antibody Engineering in the Development of Next Generation Antibody-Based Therapeutics

Brezski, R. J., & Almagro, J. C. (2012) · Springer eBooks · doi:10.1007/978-1-4419-5955-3_4 · Cited by 5

Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers

Bignucolo, A., Scarabel, L., Toffoli, G., Cecchin, E., & Mattia, E. D. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2101447 · Cited by 4

Fc engineering by monoclonal mammalian cell display for improved affinity and selectivity towards FcγRs

Wang, Z., Kang, M., Ebrahimpour, A., Chen, C., & Ge, X. (2024) · Antibody Therapeutics · doi:10.1093/abt/tbae017 · Cited by 4

FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population

Constantinides, M., Robert, N., Multrier, C., Coënon, L., Campos‐Mora, M., Jacquard, C., Gao, F., Zemiti, S., Présumey, J., Cartron, G., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2388306 · Cited by 4

Real-World Evidence of Bevacizumab and Panitumumab Drug Resistance and Drug Ineffectiveness from EudraVigilance Database

Vonica, R. C., Morgovan, C., Butucă, A., Pumnea, M., Cipăian, R. C., Frum, A., Dobrea, C. M., Vonica-Țincu, A. L., Pacnejer, A.-M., Batâr, F., et al. (2025) · Cancers · doi:10.3390/cancers17040663 · Cited by 4

Clinical Implications and Quality Assurance of Molecular Testing for EGFR-Targeting Agents in Colorectal Cancer

Vecchione, L., Saridaki, Z., & Tejpar, S. (2011) · Current Colorectal Cancer Reports · doi:10.1007/s11888-011-0112-3 · Cited by 4

Effector Cell Recruitment by Bispecific Antibodies

Kellner, C., Peipp, M., & Valerius, T. (2011) · Springer eBooks · doi:10.1007/978-3-642-20910-9_13 · Cited by 4

Role of IgG Fc Receptors in Monoclonal Antibody Therapy of Cancer

Overdijk, M. B., Verploegen, S. A. B. W., Bleeker, W. K., & Parren, P. W. H. I. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394802-1.00013-3 · Cited by 4

Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis

Morgen, E. K., Lenz, H. J., Jonker, D. J., Tu, D., Milano, G. A., Graziano, F., Zalcberg, J. R., Karapetis, C. S., Dobrovic, A., O’Callaghan, C. J., et al. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.56 · Cited by 4

EGFR/HER1 : histoire d’une cible thérapeutique

Viel, E., Curtit, E., Mansi, L., & Vignot, S. (2012) · Bulletin du Cancer · doi:10.1684/bdc.2011.1385 · Cited by 4

Cancer colorectal : les nouveaux rôles du pathologiste à l’ère de la biologie moléculaire et des thérapies « ciblées »

Svrcek, M., Cervera, P., Hamelin, R., Lascols, O., Duval, A., & Fléjou, J. (2011) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(11)70859-0 · Cited by 4

Novel Antibody-Based Proteins for Cancer Immunotherapy

Fuenmayor, J., & Montaño, R. F. (2011) · Cancers · doi:10.3390/cancers3033370 · Cited by 4

Association of FcγRIIa and FcγRIIa polymorphisms with clinical outcome in metastatic colorectal cancer patients (mCRC) treated with cetuximab and irinotecan

Bibeau, F., Crapez, E., Fiore, F. D., Thézenas, S., Sabourin, J., Lamy, A., Frébourg, T., Michel, P., Ychou, M., & Boissière‐Michot, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.11004 · Cited by 23

Genetic Polymorphisms of FcγRIIa and FcγRIIIa Are Not Predictive of Clinical Outcomes after Cetuximab plus Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer

Park, S., Hong, Y. S., Lee, J., Ryu, M., Chang, H. M., Kim, K., Ahn, Y., Na, Y.-S., Jin, D., Yu, C. S., et al. (2012) · Oncology · doi:10.1159/000335959 · Cited by 25

Role of polymorphic fc gamma receptor II/III in the efficacy of cetuximab in KRAS-NRAS-BRAF-PI3K mutated.

García‐Foncillas, J., Rodriguez, J., Boni, V., Sola, I., Honorato, B., Zárate, R., & Bandrés, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.4_suppl.477

Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer

Rodríguez, J., Zárate, R., Bandrés, E., Boni, V., Hernandez, A. B., Sola, J. J., Honorato, B., Bitarte, N., & García‐Foncillas, J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.01.007 · Cited by 82

Fc gamma receptor polymorphisms and KRAS status as predictive biomarkers in patients with metastatic colorectal cancer treated with biweekly cetuximab-based salvage therapy.

Zárate, R., Bandrés, E., Rodriguez, J., Bitarte, N., Honorato, B., Boni, V., Sola, I., Ponz‐Sarvisé, M., Garzón, C., & García‐Foncillas, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e13523